Professor Richard Scolyer, a globally respected melanoma specialist, made an extraordinary contribution to medical science after being diagnosed with terminal glioblastoma, one of the most aggressive forms of brain cancer.
Rather than accepting the grim prognosis, Scolyer chose to become the subject of his own research. Working alongside colleagues, he underwent an experimental treatment combining a triple immunotherapy regimen he helped develop, followed by surgery and a personalized cancer vaccine designed to target his specific tumour.
His remarkable journey saw him survive for about three years after his diagnosis—significantly longer than the typical survival time for patients with glioblastoma. His case has since provided valuable insights into the potential of immunotherapy in treating brain cancer. 
The pioneering approach has inspired ongoing clinical trials, raising hope for future patients battling the devastating disease.
Professor Scolyer’s courage, determination, and willingness to put himself at the centre of experimental research have left a lasting legacy in cancer medicine. He will be remembered not only as one of the world’s leading melanoma experts but also as a scientist who risked everything in the pursuit of better treatments for others.
